SEK 0.51
(-5.9%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | -27.26 Million SEK | 20.11% |
2022 | -34.12 Million SEK | -0.15% |
2021 | -34.07 Million SEK | -447.35% |
2020 | -6.22 Million SEK | 4.49% |
2019 | -6.51 Million SEK | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -6.79 Million SEK | -2.66% |
2024 Q2 | -5.72 Million SEK | 15.74% |
2023 Q2 | -8.03 Million SEK | -59.83% |
2023 Q4 | -6.62 Million SEK | 12.14% |
2023 Q3 | -7.53 Million SEK | 6.23% |
2023 Q1 | -5.02 Million SEK | 24.18% |
2023 FY | -34.77 Million SEK | -1.89% |
2022 Q1 | -5.01 Million SEK | 49.25% |
2022 FY | -34.12 Million SEK | -0.15% |
2022 Q4 | -6.63 Million SEK | 54.3% |
2022 Q3 | -14.51 Million SEK | -82.28% |
2022 Q2 | -7.96 Million SEK | -58.88% |
2021 Q4 | -9.87 Million SEK | -50.02% |
2021 Q2 | -12.54 Million SEK | -51.04% |
2021 FY | -34.07 Million SEK | -447.35% |
2021 Q1 | -8.3 Million SEK | 0.0% |
2021 Q3 | -6.58 Million SEK | 47.52% |
2020 FY | -6.22 Million SEK | 4.49% |
2019 FY | -6.51 Million SEK | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Alligator Bioscience AB (publ) | -248.98 Million SEK | 89.049% |
Ziccum AB (publ) | -21.56 Million SEK | -26.461% |
Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -66.24% |
BioArctic AB (publ) | 252.64 Million SEK | 110.792% |
Sprint Bioscience AB (publ) | -845 Thousand SEK | -3126.627% |
Mendus AB (publ) | -100.65 Million SEK | 72.911% |
Genovis AB (publ.) | 54.22 Million SEK | 150.282% |
Intervacc AB (publ) | -93.57 Million SEK | 70.864% |
QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -75.767% |
Active Biotech AB (publ) | -46.48 Million SEK | 41.345% |
Magle Chemoswed Holding AB (publ) | 18 Million SEK | 251.397% |
Bio-Works Technologies AB (publ) | -55.41 Million SEK | 50.8% |
Aptahem AB (publ) | -10.1 Million SEK | -169.823% |
Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 91.52% |
Kancera AB (publ) | -65.04 Million SEK | 58.081% |
Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 79.746% |
Fluicell AB (publ) | -26.87 Million SEK | -1.436% |
Saniona AB (publ) | -81.06 Million SEK | 66.366% |
Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -120.394% |
Biovica International AB (publ) | -126.07 Million SEK | 78.374% |
Spago Nanomedical AB (publ) | -42.5 Million SEK | 35.855% |
AcouSort AB (publ) | -17.48 Million SEK | -55.916% |
Xintela AB (publ) | -57.23 Million SEK | 52.366% |
Abliva AB (publ) | -96.54 Million SEK | 71.76% |
Egetis Therapeutics AB (publ) | -324.8 Million SEK | 91.606% |
Karolinska Development AB (publ) | -3.5 Million SEK | -677.889% |
OncoZenge AB (publ) | -15.9 Million SEK | -71.456% |
Amniotics AB (publ) | -29.07 Million SEK | 6.219% |
2cureX AB (publ) | -36.36 Million SEK | 25.02% |
CombiGene AB (publ) | -36.3 Million SEK | 24.9% |
Asarina Pharma AB (publ) | -14.64 Million SEK | -86.236% |
Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 92.907% |
Camurus AB (publ) | 532.35 Million SEK | 105.122% |
Corline Biomedical AB | -1.78 Million SEK | -1424.888% |
IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 84.917% |
Isofol Medical AB (publ) | -41.68 Million SEK | 34.59% |
I-Tech AB | 24.43 Million SEK | 211.582% |
Hansa Biopharma AB (publ) | -788.49 Million SEK | 96.542% |
Cyxone AB (publ) | -21.66 Million SEK | -25.871% |
ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 74.27% |
Cantargia AB (publ) | -290.01 Million SEK | 90.599% |
NextCell Pharma AB | -43.17 Million SEK | 36.846% |
Xspray Pharma AB (publ) | -180.76 Million SEK | 84.917% |
Elicera Therapeutics AB (publ) | -17.09 Million SEK | -59.479% |
Nanologica AB (publ) | -69.96 Million SEK | 61.029% |
SynAct Pharma AB | -224.49 Million SEK | 87.855% |
Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 38.281% |
Stayble Therapeutics AB (publ) | -23.95 Million SEK | -13.821% |
LIDDS AB (publ) | -40.67 Million SEK | 32.967% |
Lipum AB (publ) | -37.25 Million SEK | 26.813% |
BioInvent International AB (publ) | -369.94 Million SEK | 92.63% |
Alzinova AB (publ) | -16.52 Million SEK | -65.022% |
Oncopeptides AB (publ) | -253.44 Million SEK | 89.242% |
Pila Pharma AB (publ) | -6.39 Million SEK | -326.465% |
Guard Therapeutics International AB (publ) | -115.07 Million SEK | 76.306% |
Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -35.384% |
Simris Alg AB (publ) | -36.63 Million SEK | 25.577% |
Diamyd Medical AB (publ) | -146.56 Million SEK | 81.398% |
Xbrane Biopharma AB (publ) | -310.42 Million SEK | 91.217% |
Ascelia Pharma AB (publ) | -110.91 Million SEK | 75.418% |
Diagonal Bio AB (publ) | -11.56 Million SEK | -135.734% |